Spondyloarthropathies
Conference Coverage
AxSpA remission on TNFi seen in half of patients with comorbid IBD
Those who had IBD for less than 5 years and those taking adalimumab, as opposed to another TNFi, had higher likelihood of reaching axSpA remission...
News from the FDA/CDC
FDA approves Yuflyma as ninth adalimumab biosimilar
The manufacturer Celltrion is also seeking an interchangeability designation from the FDA, tentatively expected in the fourth quarter of 2024.
Conference Coverage
AxSpA effects may be more severe for Black patients
A higher percentage of Black patients had elevated erythrocyte sedimentation rate, C-reactive protein, and hip involvement in a small study. Black...
News from the FDA/CDC
FDA approves autoinjector pen for Humira biosimilar, Cyltezo
The drug will be commercially available on July 1, 2023.
Conference Coverage
Researchers make headway in understanding axSpA diagnostic delay
A pilot study finds longer delays (more than 4 years) were associated with history of uveitis, ankylosing spondylitis at diagnosis, and being in...
Conference Coverage
MACE, VTE rates compared between TNF and JAK inhibitors for AxSpA and PsA
Patients with axial spondyloarthritis and psoriatic arthritis who used JAK inhibitors did not have higher risk of myocardial infarction or stroke...
Feature
Axial spondyloarthritis versus axial psoriatic arthritis: Different entities?
Features of axial psoriatic arthritis and axial spondyloarthritis overlap, but whether they’re different diseases or on the same spectrum is...
Conference Coverage
NSAID use may mask MRI findings in a quarter of spondyloarthritis cases
Among nearly one in four patients whose MRI results were initially positive for sacroiliitis, results were negative 6 weeks after NSAIDs were...
Conference Coverage
Meta-analysis examines cancer risk concern for JAK inhibitors
Although no increased cancer risk was seen vs. methotrexate or placebo, Janus kinase inhibitors were associated with a higher cancer risk than...
Feature
Biosimilars and patients: Discussions should address safety, cost, and anxiety about change
Physicians can respond to pushback from patients on switching to a biosimilar by offering resources and discussing options for both biosimilar and...
News from the FDA/CDC
FDA approves new formulation of Hyrimoz adalimumab biosimilar
The agency approved a higher-concentration formulation of Hyrimoz for its previous indications, including rheumatoid arthritis and psoriasis.